
Site burden is now measured through satisfaction surveys, in-the-moment check-ins, and adoption patterns, but each method catches a different moment, and the gaps between them decide whether teams can act before burden becomes risk.
IQVIA's Institute for Human Data Science's Study found a record number of new drugs launched in the United States in 2018. A third of the new drugs identified as innovative therapies with novel mechanisms of action different from existing therapies. Additionally, the study found that the likelihood that a drug entering clinical development would be a success was 11 percent, down three percent the previous year. Eight trends were also identified as possibilities to increase R&D productivity by double digits over next five years.
Read more of the study






